Current Report Filing (8-k)
March 15 2018 - 04:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 15, 2018
Infinity Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
000-31141
|
|
33-0655706
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
784 Memorial Drive, Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 453-1000
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 15, 2018, we issued a
press release announcing our results for the year ended December 31, 2017 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this
Current Report on Form
8-K
and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.
This information and Exhibit 99.1 hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act
of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) The following exhibit is
included in this report:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
INFINITY PHARMACEUTICALS, INC.
|
|
|
|
|
Date: March 15, 2018
|
|
|
|
By:
|
|
/s/ Seth A. Tasker
|
|
|
|
|
|
|
Seth A. Tasker
|
|
|
|
|
|
|
VP & General Counsel
|
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Mar 2023 to Mar 2024